# Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer

> **NCT00112918** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 3451 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **DRUG:** Capecitabine
- **DRUG:** 5-Fluorouracil (5-FU)
- **DRUG:** Leucovorin calcium
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT00112918
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2010-06
- **Final completion:** 2012-06
- **Target enrollment:** 3451 (ACTUAL)
- **Last updated:** 2013-08-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00112918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00112918, "Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00112918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*